Sir, We read with interest the article by Capalbo et al. (2013) , which describes the use of array comparative genomic hybridization (aCGH) for the sequential analysis of the 1st and 2nd polar bodies (PBs), single blastomeres and trophectoderm (TE) biopsies, derived from a small group of reproductively older women (aged 40 years or over). On the basis of their results, Capalbo et al. question the accuracy of PB testing. Although we commend the authors for attempting a technically challenging study, we believe there are alternative interpretations of their data that should also be considered.
Their judgement concerning the accuracy of PB testing is based upon the presumption that results obtained from trophectoderm (TE) biopsy provide the most accurate assessment of the inner cell mass of the blastocyst. Thus, if the diagnosis obtained from the PBs disagrees with that of the TE, it is assumed that the PB result is incorrect. However, it is well known that TE analysis has a measurable error rate, due, in large part, to chromosomal mosaicism (Northrop et al., 2010; Fragouli et al., 2011a) . The possibility of mosaicism is acknowledged by Capalbo et al. and yet, when coming to conclusions concerning the accuracy of PB analysis, they continue to treat TE results as definitive.
We also have some concerns about the way that PBs were processed and analysed, as the proportion of second PBs that failed to yield a diagnostic result was higher than in previous studies (Fragouli et al., 2011b; Magli et al., 2011) . Moreover, the authors state that when assessing abnormalities affecting the 1st PB 'it was not possible to systematically distinguish between whole chromosomes versus single chromatids'. This is surprising as these two types of abnormality can be readily identified using aCGH (Gabriel et al., 2011; Handyside et al., 2012) . An inability to accurately distinguish between chromosome and chromatid abnormalities could lead to misdiagnosis, potentially explaining some of the inconsistencies between PB and blastocyst analysis in the samples examined.
Although we write this letter in support of PB analysis, we agree that further research needs to be undertaken to verify the accuracy of this approach. Indeed, it was our group that first suggested that mechanisms such as anaphase lag could lead to errors in PB analysis (Wells et al., 2012) . Capalbo et al. also considered this idea after confirming that chromosome loss is common during preimplantation development. A high rate of chromosome loss makes the conversion of some oocyte-derived trisomies to disomies (normality) inevitable. Does this mean that PB analysis cannot accurately predict the karyotype of blastocysts? What this interpretation fails to take into account is that the aneuploid oocytes produced by women of advanced reproductive age typically contain more than one abnormal chromosome (.80% of oocytes in Capalbo's study had more than one aneuploidy and the average number of errors per oocyte was almost 4). Although it may be true that some individual trisomies can be 'corrected', the embryo almost always retains additional abnormalities and therefore remains aneuploid. In the study by Capalbo and co-workers 100% of the oocytes diagnosed abnormal following PB analysis produced embryos with abnormal TE results, just as originally predicted. It seems fair to question whether PB analysis would be accurate if applied to younger patients, who tend to produce oocytes with only one aneuploid chromosome (although in most countries such patients are rarely offered PB testing). Further investigations will be needed to answer this question.
If subsequent studies confirm that the rescue of oocyte-derived trisomies is common, resulting in chromosomally normal embryos, this may have negative implications for analysis at the blastocyst stage as well as for PB testing. As Capalbo et al. point out, one-third of trisomy rescue events produce an embryo with a uniparental disomy (UPD) where both chromosome copies are derived from the same parent. Blastocysts with UPD appear entirely normal using aCGH, yet are at elevated risk of recessive disorders, due to homozygosity for regions of the affected chromosome. Additionally, they will be affected by imprinting disorders if the chromosome involved carries any imprinted genes.
In our laboratory, analysis at the blastocyst stage is the preferred approach for aneuploidy screening. This permits analysis of aneuploidies originating from both the sperm and the oocyte. Furthermore, the blastocyst is more robust than the cleavage stage embryo and therefore less likely to be damaged by the biopsy procedure. However, this approach is not suitable for every patient, an important point, not acknowledged in the Capalbo study. Women of advanced reproductive age (the largest group referred for chromosome screening) often generate low numbers of oocytes and even fewer blastocysts. We suggest that, for such patients, analysis of the PBs is still worthy of consideration. We eagerly await the results of the ongoing clinical trial into PB-based PGS, organized by ESHRE, which should provide conclusive information concerning the clinical utility of PB analysis. Questions about the accuracy of polar body analysis for preimplantation genetic screening Sir, Based on chromosome copy number analysis in the first and second polar bodies (PB1 and PB2) by array comparative genomic hybridization (CGH), Capalbo et al. (2013) recently compared the predicted incidence of aneuploidies of maternal meiotic origin with aneuploidies detected in single blastomeres biopsied at cleavage stages and a biopsied sample of trophectoderm cells in a series of embryos, which developed to the blastocyst stage, in women over the age of 40. Because they find additional and/or missing aneuploidies at the later stages, they conclude that for preimplantation genetic screening (PGS) in women of advanced maternal age, polar body analysis is relatively ineffective. Furthermore, they provide limited molecular genetic evidence of two examples in which a predicted maternal trisomy was 'rescued' in the trophectoderm cells. However, we believe that their experimental design is flawed, their interpretation misleading and argue that in fact their data supports completely the opposite conclusion in these highly selected embryos.
As chromosomal mosaicism, arising through malsegregation of chromosomes in the early mitotic divisions following fertilization, is common in cleavage stage embryos, it is not surprising that there were discrepancies between the maternal aneuploidies predicted by polar body analysis and those identified in the single biopsied blastomeres. At the blastocyst stage, although there is a general consensus that the incidence of mosaicism is lower, there is evidence that mitotic errors continue to arise and that chromosome copy number is not always concordant between multiple biopsies of small numbers of trophectoderm cells or with the inner cell mass. In addition, blastocysts derived from mosaic cleavage stage embryos, as identified in the single blastomeres, are presumably also more likely to be mosaic. We believe therefore that it would have been much more meaningful if either all blastomeres had been analysed at cleavage stages (precluding any follow-up at the blastocyst stage) or that multiple trophectoderm biopsies and the remaining inner cell mass containing fragment had been analysed following single cell biopsy at cleavage stages. Only in this way, can the evolution of meiotic and mitotic errors be assessed properly.
Capalbo et al. state that only 79.5% (62/78) of predictions (either for normal copy number or aneuploidy) based on polar body analysis were confirmed in the embryo giving the misleading impression that polar body analysis is not very accurate. However, this is based on the aneuploidies detected in the trophectoderm cells biopsied at the blastocyst stage. In fact, in the single blastomeres, 94% (73/78) of predictions were confirmed as correct. This compares well with our recent study in which we followed up polar body analysis with array CGH analysis of the whole cleavage stage embryo (Christopikou et al., 2013) . In our study, 93% (65/70) of aneuploidies detected in the cleavage stage embryos were associated with copy number changes in the polar bodies and all but one of these had been predicted accurately. Taken together, this provides strong evidence that polar body analysis has a high sensitivity for predicting aneuploidies of maternal meiotic origin. However, in both studies there were a number of false-positive chromosome copy number changes in polar bodies that did not result in the expected copy number in the embryo. These need further investigation by molecular genetic methods such as single nucleotide polymorphism genotyping and karyomapping (Handyside et al., 2010) , which can identify each parental chromosome.
Overall, Capalbo et al. conclude that for PGS in advanced maternal age, biopsy and analysis at the most advanced blastocyst stage is essential to capture both paternal and maternal meiotic aneuploidies together with aneuploidies resulting from mitotic errors occurring after fertilization. On the contrary, we would argue that it is well established that errors arising in female meiosis are by far the predominant cause of pregnancy loss, abnormal pregnancy and live birth with an incidence 5 -10-fold higher than paternal meiotic errors. It therefore makes sense to target female meiotic errors
